Following the news that Novo Nordisk made an unsolicited acquisition bid for US-based obesity biotech Metsera Therapeutics, which was subsequently rejected by Pfizer, but designated... The post Metsera takeover battle reflects Novo Nordisk and Pfizer push to challenge Lilly’s obesity drug dominance, says GlobalData appeared first on GlobalData.| GlobalData
Once so valuable its market capitalization eclipsed that of its home country of Denmark, pharmaceutical giant Novo Nordisk is now showing signs of strain. Most recently, several members of Novo Nordisk’s board of directors quit after failing to reach an agreement with the Novo Nordisk Foundation, the firm’s controlling shareholder (via Novo Holdings), on the… The post Novo Nordisk board chair and members quit after disagreement on board membership appeared first on Drug Discovery and De...| Drug Discovery and Development
It took just one off-hand comment during a White House event about fertility treatments for President Trump to temporarily wipe tens of billions from the market cap of the world’s leading obesity drugmakers. Trump’s vow Thursday to bring Ozempic down to $150 per month, calling it “the fat-loss drug,” sent Novo Nordisk shares down 6.3%… The post Trump’s $150 Ozempic vow hits Novo, Lilly, even as Oz says ‘we have not negotiated those yet’ appeared first on Drug Discovery and Dev...| Drug Discovery and Development
Novo Nordisk has laid off dozens of employees at its plant in North Carolina, an analysis of LinkedIn posts by Reuters found. The layoffs come after the company announced a plan to cut 9,000 jobs globally in an effort to compete with Eli Lilly last month. The exact number of layoffs at the Clayton plant… The post Novo Nordisk lays off dozens of US employees at NC plant appeared first on Drug Discovery and Development.| Drug Discovery and Development
Η φαρμακευτική εταιρεία Novo Nordisk ανακοίνωσε ότι μέχρι το τέλος του έτους θα προχωρήσει στην απόσυρση τεσσάρων προϊόντων ινσουλίνης από την ελληνική αγορά. Όπως διευκρινίζει, σε σχετική ανακοίνωσή, ο Εθνικός Οργανισμός Φαρμάκων (ΕΟΦ), η απόφαση αυτή δεν σχετίζεται με θέματ...| Healthstories.gr – υγεία, διατροφή, ομορφιά, φυσικ...
Has BridgeBio's business model worked? How are executives at Moderna dealing with the company's slump? Find out on the new episode of "The Readout LOUD."| STAT
Proposta reflete mudanças mais amplas nos hábitos gastronômicos e uma tentativa de tornar os cardápios mais acessíveis para aumentar as vendas, segundo o CEO Rick Cardenas| Bloomberg Línea Brasil
